Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe·2016·New England Journal of Medicine
DOI 10.1056/nejmoa1607751

Cited by (1,433)

Items 1,301–1,400 of 1,433

  1. Re: Arcuri and Americo “Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis”
    Faith E. Davies, Eleanor Saunders, F. Bourhis, Patricia Guyot · 2022 · Annals of Hematology
  2. Daratumumab for Immunoglobulin Light Chain Amyloidosis
    Foteini Theodorakakou, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2021 · touchREVIEWS in Oncology & Haematology
  3. 14 / YouTube™ and Multiple Myeloma
    Khan Muhammad Azeem · 2018
  4. Belantamab mafodotin for relapsed or refractory multiple myeloma
    Manuel David Gil‐Sierra, María Del Pilar Briceño-Casado · 2022 · Journal of Oncology Pharmacy Practice
  5. Impact of Daratumumab on Anti-HLA Antibodies Level in Patients with Multiple Myeloma
    Floriane Theves, David Kheav, Alexis Talbot et al. · 2022 · Research Square
  6. The clinical value of circulating cell free DNA in multiple myeloma
    Tong Yang, Wei‐Min Chen, Zhihong Wang, Tiannan Wei, Jin Shang, Yun Hsiao Lin · 2022 · Research Square
  7. Impact of daratumumab on anti-HLA antibodies level in patients with multiple myeloma
    Bertrand Arnulf, Floriane Theves, David Kheav et al. · 2022 · Research Square
  8. Daratumumab
    Vu Minh Hua · 2021 · Resistance to targeted anti-cancer therapeutics
  9. Real-world Drug Regimens for Multiple Myeloma in a Swiss Population (2012 to 2017): cost-outcome description
    Klaus Eichler, Roland Rapold, Simon Wieser · 2019 · medRxiv
  10. Targeted Treatments for Hematological Cancers
    Elaine Vickers PhD · 2018 · Wiley eBooks
  11. Multiple myeloma
    Michel Delforge · 2018 · HemaSphere
  12. Cost Saving with Home-Based Chemotherapy Approach in Multiple Myeloma: The ADHOMY Trial
    Samantha Schulmann, Hamza Achit, Lauriane Filliatre‐Clement, Cécile Di Santolo, Marine Ferry, Jean Vigneron, Pauline Barbier-Lider, Sophie Morice, Arnaud Campidelli, Luciane Schirmer et al. · 2021 · Research Square
  13. Multiple Myeloma
    Kirollos S. Hanna · 2017 · The American Pharmacists Association eBooks
  14. Comparison of Monoclonal Antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus Dexamethasone/Prednisone for the treatment of Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
    Ye Wu, Xia Wu, Xiaoyan Liu, Xue Li Zheng, Jili Deng, Yuping Gong · 2020 · Research Square
  15. Multiples Myelom
    Martin Gramatzki, Andreas Günther · 2016 · Springer eBooks
  16. Myélome multiple
    Xavier Armoiry, G. Aulagner, A.-M. Henaine · 2020 · Elsevier eBooks
  17. New drug: Daratumumab for multiple myeloma
    2017 · Australian Prescriber
  18. Antibody Therapies for Multiple Myeloma
    Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos · 2021 · IntechOpen eBooks
  19. Lenalidomide
    Adrian Jun-Ting Yeung, Silvia Ling · 2021 · Resistance to targeted anti-cancer therapeutics
  20. Cancers of the Blood
    Surya Kanta De · 2022 · Wiley eBooks
  21. Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting
    Murielle Lalive d’Epinay, Sabine Güsewell, Nicole Graf, Ulrich Mey, Christoph Driessen, Felicitas Hitz · 2022 · Hematological Oncology
  22. El problema ético de la limitación del acceso a beneficios en salud : el caso de los medicamentos innovadores
    Mauricio Sanabria · 2020
  23. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
    Joshua Ryan Richter, Peggy L. Lin, Viviana García-Horton · 2022 · Research Square
  24. Interference Analysis of Monoclonal Antibody Cluster of Differentiation 38 on ABO Blood Group Identification and Cross-Matching
    Xuechun Wang, Hongmei Qiu, Yan Shao, Yicen Chen · 2022 · Indian Journal of Pharmaceutical Sciences
  25. EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit
    Ajay K. Nooka, Sagar Lonial · 2022 · Clinical Lymphoma Myeloma & Leukemia
  26. Evaluación de estrategias inmunes para el control del mieloma múltiple a largo plazo
    Julio Dávila Valls · 2022 · Gredos (University of Salamanca)
  27. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients
    Zdeněk Adam, Luděk Pour, Marta Krejčí, David Zeman, Zdeněk Řehák, Renata Koukalová, Viera Sandecká, Martin Štork, Zdeněk Král · 2022 · Onkologie
  28. Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab
    Marianna Palazzo, Gaia Ciolli, Sofia Pilerci, Irene Attucci, Ludovica Pengue, Alessandro Maria Vannucchi, Elisabetta Antonioli · 2022 · Frontiers in Hematology
  29. Monoclonal Antibody and Targeted Toxin Therapy
    Robert C. Bast, Michael R. Zalutsky · 2022 · Wiley eBooks
  30. Plasma Cell Disorders
    Andrew Jenho Yee, Teru Hideshima, Noopur S Raje, Kenneth Carl Anderson · 2022 · Wiley eBooks
  31. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Karthik Nath, Tala Shekarkhand, Meghan Salcedo, Andriy Derkach, Siobhan Rueda, Aisara Chansakul, Malin Hulcrantz, Neha Korde, Urvi Ashok Shah, Carlyn Rose C. Tan et al. · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
  32. Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test
    Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri · 2022 · AboutOpen
  33. Management of Relapsed and Refractory Multiple Myeloma: Recent advances
    Krishnakumar Rathnam, S. V. Saju, Honey Susan Raju · 2022 · Indian Journal of Medical and Paediatric Oncology
  34. CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4
    Ľuboš Drgoňa, Lucia Masárová · 2022 · Springer eBooks
  35. Novel and Experimental Clone-Directed Therapies
    Mohamed Elemary, Ibraheem Othman · 2022 · Springer eBooks
  36. Hämatologische Neoplasien und solide Tumore
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2022 · Springer eBooks
  37. Immunotherapy for Multiple Myeloma
    Anthony A. Oyekunle · 2023 · Springer eBooks
  38. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  39. Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
    Hyunsoo Cho, Kyung Hwan Kim, Hoyoung Lee, Chang Gon Kim, Haerim Chung, Yoon Seok Choi, Su‐Hyung Park, June‐Won Cheong, Yoo Hong Min, Eui‐Cheol Shin et al. · 2023
  40. Data from The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
    Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Fabian Beier, Linda Röhner, Andrej Stoll, Michael Rehli, Claudia Gebhard, Christopher Lischer, Martin Eberhardt et al. · 2023
  41. Improving immunotherapeutic treatment strategies for relapsed/refractory multiple myeloma patients
    Kristine A. Frerichs · 2023
  42. Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma
    Pingping Chen, Jiexian Ma, Wensi Qian · 2023 · Minerva Pediatrics
  43. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
    Q Q Wang, Yao Li, Menglei Zhu et al. · 2023 · PubMed
  44. Multiple myeloma management: What comes after lenalidomide-based therapy?
    Martha Louzada · 2022 · Canadian Hematology Today
  45. Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies
    Irit Mazza Avivi, Naama Yekutiel, Tamir Shragai · 2023 · Annals of Hematology
  46. Amiloidosis sistémica con énfasis en amiloidosis de cadenas livianas de inmunoglobulinas
    Kenny Gálvez · 2023 · Medicina y Laboratorio
  47. Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
    Aimaz Afrough, Shebli Atrash, Barry A. Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Abed Alkharabsheh, Hamza Hashmi, Al-Ola A. Abdallah · 2023 · Cancers
  48. Exploring clinical and economic value of novel therapies in oncology; contemporary challenges and applications
    Mahmoud Hashim · 2023
  49. The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure
    Jose Maciel Larios, Howard R. Terebelo · 2023 · Medical Research Archives
  50. Panorama actualizado en mieloma m�ltiple
    José Luis Álvarez-Vera, Martha Alvarado‐Ibarra, José A. de la Peña-Celaya, Eleazar Hernández-Ruiz, Luara Luz Arana-Luna, Leire Montoya-Jiménez, Ma. Eugenia Espitia-Ríos, Cynthia Pelayo Mena, Rosalinda Peñaloza-Ramírez, Juan M. Pérez-Zúñiga · 2023 · Revista de especialidades m�dico-quir�rgicas
  51. HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation
    Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Mutsumi Hayashi, Chikao Morimoto, Taketo Yamada · 2024 · Cancer Research Communications
  52. Review of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”
    Mobil Akhmedov, Pervin A. Zeynalova · 2024 · Oncohematology
  53. Onkoloji
    Mahmut Büyükşimşek, Mert Tohumcuoğlu, Ali Murat Sedef, Aykut Bahçeci, Erdinç Nayır, Mesut Yılmaz, Yasemin Bakkal Temi, Ali Ayberk Beşen, Ömer Diker, Melih Şimşek et al. · 2022 · Akademisyen Kitabevi eBooks
  54. Multiple Myeloma
    Mohammad Biglari, Sahar Tavakoli Shiraji · 2024 · Elsevier eBooks
  55. Investigation of the Serotonin, Cortisol Hormones and some Biochemical Parameters in Patients with Beta Thalassemia in Thi-Qar Governorate /Iraq
    Noor Alazraqi, Leila Sadeghi, Gholamreza Dehghan · 2024 · University of Thi-Qar Journal of Science
  56. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
    Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa et al. · 2024 · Annals of Hematology
  57. The Perspective of Romanian Patients on Continuous Therapy for Multiple Myeloma
    Ruxandra Maria Irimia, Sorina Nicoleta BADELITA, Sinziana Barbu, Larisa Emilia Zidaru, Ioana Loredana Carlan, Oana Diana Preda, Daniel Coriu · 2024 · Journal of Personalized Medicine
  58. Role of dithiothreitol in the resolution of pretransfusion immunohematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
    Anshika Yadav, Pankaj K. Agarwal, Gajendra Nath Gupta · 2024 · Asian Journal of Transfusion Science
  59. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
    Vânia Hungria, Anna Maria Sureda, Garcia Campelo, Marco Aurélio Salvino, Karthik Ramasamy · 2024 · Cancers
  60. Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
    Diala Alhaj Moustafa, Laila Shafei, Ruba Sulaiman, Mohamed A. Yassin, Dina Abushanab, Yousef Algarabli, Daoud Al‐Badriyeh · 2024 · Journal of Oncology Pharmacy Practice
  61. Light-Chain Myeloma Presented as Osseus Tumors: A Case Report
    Sihui Huang, Mustafa Wasifuddin, Amulya Bellamkonda · 2024 · Journal of Investigative Medicine High Impact Case Reports
  62. Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Edvan de Queiroz Crusoé, Joanna Suzana Leal Ribeiro dos Santos, Juliana de Andrade Santos et al. · 2025 · Blood Neoplasia
  63. Multiple myeloma
    Karthik Ramasamy, Sagar Lonial · 2025 · Wiley eBooks
  64. Cure for multiple myeloma?
    Klaus Podar · 2025 · memo - Magazine of European Medical Oncology
  65. Hämatologische Neoplasien und solide Tumore
    Wolf-Dieter Ludwig, Arnold Ganser, Georg Maschmeyer · 2025 · Springer eBooks
  66. Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
    Andrew Whiteley, Stephen C. Ijioma, David Ray, Spencer S. Langerman, Ellen Hu, Amy E. Pierre, Tomer Martin Mark, Habte Aragaw Yimer · 2025 · Current Oncology
  67. Temporal Trends in Multiple Myeloma Mortality and Their Relationship to Evolving Treatment Strategies: A Retrospective Analysis Using SEER Data
    Navkirat Kahlon · 2025 · Research Square
  68. Research Progress on Drug Combination Therapy for Multiple Myeloma
    Zixi Zhang · 2025 · Theoretical and Natural Science
  69. Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis
    Satoshi Hirano, Keisuke Hanada, Hideki Maeda · 2025 · Scientific Reports
  70. Plasma cell disorders
    Caitlin L. Costello, Rafaël Fonseca · 2022
  71. A case of POEMS syndrome presenting craniocervical vascular stenosis
    Minori Sawada, Gaku Okumura, Ken Takasone · 2025 · Rinsho Shinkeigaku
  72. Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma
    Caitlin L. Costello · 2025
  73. Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma
    Hongmei Zhou, Min Zhang, Yi Jin, Xianghua Lang · 2025 · Hematology
  74. Das Multiple Myelom im Detail
    Francesca Gay, Edoardo Marchetti, Giuseppe Bertuglia · 2025 · Kompass Onkologie
  75. Immunotherapy for Multiple Myeloma
    Anthony A. Oyekunle · 2025 · Springer eBooks
  76. Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy
    S. Ito, Takashi Hamada, Masaru Nakagawa et al. · 2025 · Hematology Reports
  77. Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma
    Singh Sandeep, Vivek Uttam, Shafiul Haque, Hardeep Singh Tuli, Pallavi Mishra, Aklank Jain · 2025 · Cancer Treatment and Research Communications
  78. Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience
    Oscar C. Y. Yang, Yi‐Hao Chiang, Caleb Gon‐Shen Chen, Yu‐Cheng Chang, Ming‐Chih Chang, Huan‐Chau Lin, Johnson Lin, Ken‐Hong Lim · 2025 · Cancer Reports
  79. Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review
    Chiel Gharakhani, Alexander Soetens, Wouter C. J. Huysse · 2025 · Acta Clinica Belgica
  80. The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    Turkan Aliyeva, Haroon Alamy, Feras Ahmad Ibrahim Ahmad, Julia Natche, Hafiz Shah, Vrushali Shelar, Huu Than Huynh, Imane El Amri · 2025 · Current Research in Translational Medicine
  81. Additional file 1 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
    Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Tadao Ishida, Yamamoto, Junichi, Ito, Takumi, Muneyoshi Futami, Ri, Masaki et al. · 2021 · Figshare
  82. Additional file 1 of Minimal residual disease in multiple myeloma: current status
    Ding, Hong, Xu, Juan, Lin, Zhimei, Huang, Jingcao, Wang, Fangfang, Yang, Yan, Cui, Yushan, Luo, Hongmei, Gao, Yuhan, Xinyu Zhai et al. · 2021 · Figshare
  83. Additional file 2 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
    Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Tadao Ishida, Yamamoto, Junichi, Takumi Ito, Muneyoshi Futami, Ri, Masaki et al. · 2021 · Figshare
  84. Additional file 1 of Measurable residual disease in multiple myeloma: ready for clinical practice?
    Burgos, Leire, Puig, Noemi, Cedena, Maria-Teresa · 2020 · Figshare
  85. Additional file 3 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
    Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Tadao Ishida, Yamamoto, Junichi, Takumi Ito, Muneyoshi Futami, Masaki Ri et al. · 2021 · Figshare
  86. Additional file 1 of Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
    Ye, Wu, Wu, Xia, Liu, Xiaoyan, Xue Li Zheng, Deng, Jili, Gong, Yuping · 2021 · Figshare
  87. Additional file 1 of Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
    Shebli Atrash, Philippe Thompson‐Leduc, TAI, Ming-Hui, Shuchita Kaila, Kathleen S Gray, Isabelle Ghelerter, LAFEUILLE, Marie-Hélène, Patrick Lefèbvre, ROSSI, Adriana · 2021 · Figshare
  88. Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed‐Refractory Multiple Myeloma ( RRMM ) Aged 70 and Above: A Multicenter Study
    Razan A. Mansour, Kimberly M. Green, Chandler Graf, Mark Chang, Gray Magee, James A. Davis, Anas Zayad, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze et al. · 2026 · European Journal Of Haematology
  89. Evaluating Limited-Duration DRd Treatment in Biochemical and Clinical Relapse of Multiple Myeloma: A Taiwan-Based Analysis
    Lingjung Chiu, Ming-Chung Wang, Ming‐Chun Ma, Hung-Lin Liu, Bi-Han Liao, Ching-Yuan Kuo · 2026 · Research Square
  90. An atypical POEMS-like paraneoplastic syndrome associated with IgA κ smoldering multiple myeloma treated with daratumumab
    Tanushree Bhatt, Bhuwan Bhatta, Alexander Johnston · 2026 · Current Problems in Cancer Case Reports
  91. Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
    Sarah Mettias, Jamie Cheung, Jonathan Moore, James R. Berenson · 2026 · Case Reports in Oncology
  92. Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents
    Farah Alam, Huma Siddiqui, Arpna Nihal, Madiha Andleeb, Amna Qamar uz Zaman, Mehwish Imam Khushk, Fatima Hussain, Rahul Rai, Fasiha Fatima, Danaish Kumar et al. · 2026 · World Journal of Methodology
  93. Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab
    Naveen G. Subramanian, Fleur M. Aung, Zachary Hunzeker, Krina K. Patel, Hans Chulhee Lee, Shida Jin, Elliana J. Young, Roland L. Bassett, Cristhiam Mauricio Rojas Hernandez · 2026 · Discover Medicine
  94. Hämatologische Neoplasien und solide Tumore
    Arnold Ganser, Bernd Hertenstein, Wolf‐Dieter Ludwig · 2026 · Springer eBooks
  95. Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance
    Oren Pasvolsky, Curtis Marcoux, Denái R. Milton et al. · 2026 · Clinical Lymphoma Myeloma & Leukemia
  96. A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)
    Yuxin Liu, Ji Hyun Lee, Clifton Craig Mo, Taya Jamal Salman, Shahrier Hossain, Shonali Midha, Omar Nadeem, Taylor Nicholson, Jessica Croteau, Natalie Kazierad et al. · 2026 · Expert Opinion on Biological Therapy
  97. Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection.
    Samer al Hadidi, C. Costello, Luciano J. Costa, B. Dhakal, Peter Georges, A. Gajra, Yi Lin, R. Bhargava, Agne Paner-Straseviciute, Ravi Vij · 2026 · Clinical Lymphoma, Myeloma & Leukemia
  98. Management and Evolution of Multiple Myeloma with Renal Failure in Developing Countries: The Case of the Sylvanus Olympio University Hospital in Lome, Togo
    Kossi Akomola SABI, Eyram Fianyo, Yoan Makafui Amekoudi · 2022 · Open Journal of Nephrology
  99. Développement et évaluation d'anticorps bispécifiques dans le traitement du Myélome multiple
    Maxime Fayon · 2019 · theses.fr (ABES)
  100. Développement de nouveaux radiopharmaceutiques à base de cuivre-64 pour application théranostique en cancérologie
    Anne-Sophie Navarro · 2020 · theses.fr (ABES)